Literature DB >> 16034125

Critical role for IgM in host protection in experimental filarial infection.

Bhargavi Rajan1, Thirumalai Ramalingam, Thiruchandurai V Rajan.   

Abstract

We have previously shown that B cells (in particular B1 cells) are important in host protection against brugian infections in a murine i.p. model. In this study, we show that mice deficient in circulating IgM (secIgM-/-), but otherwise normal in their humoral responses, manifest a significant impairment in worm elimination, suggesting that one critical B cell function is the production of Ag-specific IgM. Efficient elimination of larvae is IgM dependent for both primary and challenge infections. The ability to eliminate worms is restored in secIgM-/- mice by administering sera from primed mice. We corroborated these in vivo studies with in vitro observations which show that IgM is the only isotype that reacts strongly with the surface of Brugia L3. Furthermore, activated peritoneal exudate cells adhere to L3 only in the presence of filaria-specific sera or IgM purified from them. This attachment is not reduced by heat inactivation of the serum, suggesting complement independent activity. Peritoneal exudate cells from primed mice, especially activated macrophages, carry high levels of IgM on their surfaces. Our observations suggest that an IgM-mediated reaction initiates the formation of host-protective granulomas.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16034125     DOI: 10.4049/jimmunol.175.3.1827

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  30 in total

Review 1.  The importance of natural IgM: scavenger, protector and regulator.

Authors:  Michael R Ehrenstein; Clare A Notley
Journal:  Nat Rev Immunol       Date:  2010-10-15       Impact factor: 53.106

2.  Granuloma formation around filarial larvae triggered by host responses to an excretory/secretory antigen.

Authors:  Yashodhara Dash; Manish Ramesh; Ramaswamy Kalyanasundaram; Gnanasekar Munirathinam; Leonard D Shultz; T V Rajan
Journal:  Infect Immun       Date:  2010-11-15       Impact factor: 3.441

Review 3.  Antibody-mediated protection through cross-reactivity introduces a fungal heresy into immunological dogma.

Authors:  Arturo Casadevall; Liise-anne Pirofski
Journal:  Infect Immun       Date:  2007-08-20       Impact factor: 3.441

Review 4.  A comprehensive, model-based review of vaccine and repeat infection trials for filariasis.

Authors:  C Paul Morris; Holly Evans; Sasha E Larsen; Edward Mitre
Journal:  Clin Microbiol Rev       Date:  2013-07       Impact factor: 26.132

5.  Immune Surveillance by Natural IgM Is Required for Early Neoantigen Recognition and Initiation of Adaptive Immunity.

Authors:  Shaikh M Atif; Sophie L Gibbings; Elizabeth F Redente; Faye A Camp; Raul M Torres; Ross M Kedl; Peter M Henson; Claudia V Jakubzick
Journal:  Am J Respir Cell Mol Biol       Date:  2018-11       Impact factor: 6.914

Review 6.  Human innate lymphoid cells (ILCs) in filarial infections.

Authors:  S Bonne-Année; T B Nutman
Journal:  Parasite Immunol       Date:  2017-06-15       Impact factor: 2.280

Review 7.  Carbohydrate vaccines: developing sweet solutions to sticky situations?

Authors:  Rena D Astronomo; Dennis R Burton
Journal:  Nat Rev Drug Discov       Date:  2010-04       Impact factor: 84.694

Review 8.  Immunopathogenesis of lymphatic filarial disease.

Authors:  Subash Babu; Thomas B Nutman
Journal:  Semin Immunopathol       Date:  2012-10-03       Impact factor: 9.623

9.  Immunoprophylaxis of multi-antigen peptide (MAP) vaccine for human lymphatic filariasis.

Authors:  Christiana Immanuel; Aparnaa Ramanathan; Malathi Balasubramaniyan; Vishal Kishor Khatri; Nitin Purushottam Amdare; Donthamsetty Nageswara Rao; Maryada Venkata Rami Reddy; Kaliraj Perumal
Journal:  Immunol Res       Date:  2017-06       Impact factor: 2.829

Review 10.  IgM in microbial infections: taken for granted?

Authors:  Rachael Racine; Gary M Winslow
Journal:  Immunol Lett       Date:  2009-06-17       Impact factor: 3.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.